Histerosonografia

[pic]
Skip to main page content
• HOME
• CURRENT
• ARCHIVE
• COLLECTIONS
• 中国 (ABSTRACTS)
• RADIOLOGY SELECT
• RADIOGRAPHICS
• RSNA.org
Principio del formulario
Search [pic][pic]GO[pic]

Advanced Search

Final del formulario
• John Lesser
• View/Change User Information
• Sign Out
•

• Expand+
Radiologyradiology.rsna.org
1. doi:10.1148/radiol.2203010011 September 2001 Radiology, 220, 765-773.
Endometrial Evaluation with Transvaginal US and Hysterosonography in Asymptomatic Postmenopausal Women with Breast Cancer Receiving Tamoxifen1
1. Katherine Fong, MB, BS, FRCPC,
2. Rose Kung, MD, MSc, FRCSC,
3. Alice Lytwyn, MD, MSc, FRCPC,
4. Maureen Trudeau, MD, FRCPC,
5. William Chapman, MD, FRCPC,
6. PatriciaNugent, MB, BS, FRCPC,
7. Phyllis Glanc, MD, FRCPC,
8. Lee Manchul, MD, FRCPC,
9. Diane Szabunio, RDMS and
10. Terri Myhr, MSc
+ Author Affiliations
1. 1From the Departments of Medical Imaging (K.F., P.N., P.G., D.S.), Obstetrics and Gynecology (R.K.), Pathology (A.L.), and Medical Oncology (M.T.), Sunnybrook and Women’s College Health Sciences Centre, 76 Grenville St, Toronto, Ontario,Canada M5S 1B2; the Departments of Pathology (W.C.) and Radiation Oncology (L.M.), Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada; and the Centre for Research in Women’s Health, University of Toronto, Ontario, Canada (T.M.). From the 2000 RSNA scientific assembly. Received November 26, 2000; revision requested January 22, 2001; revision received March 9; acceptedApril 3. Supported by the Canadian Breast Cancer Foundation (Ontario Chapter) and the Helen and Paul Phelan Foundation. Address correspondence to K.F. (e-mail: katherine.fong@swchsc.on.ca).
 
Next Section
Abstract
PURPOSE: To determine performance characteristics of transvaginal ultrasonography (US) and hysterosonography for diagnosing endometrial abnormality in asymptomatic postmenopausal womenwith breast cancer receiving tamoxifen.
MATERIALS AND METHODS: The authors prospectively examined 138 women receiving tamoxifen by using transvaginal US, hysterosonography, and office hysteroscopy. The combined hysteroscopic-histopathologic diagnosis was the reference standard. Sensitivity, specificity, positive and negative predictive values, and likelihood ratios of transvaginal US andhysterosonography were calculated.
RESULTS: All 138 women underwent transvaginal US; 104, successful hysterosonography; and 117, successful hysteroscopy. Uterine abnormality was present in 47 (40.2%) of 117 women: 45 with polyps and two with submucosal fibroids. Receiver operating characteristic curve analysis revealed 6 mm to be the optimal endometrial thickness cutoff for diagnosing endometrialabnormalities. When a thickness greater than 6 mm or a focal endometrial finding was considered abnormal, transvaginal US had a sensitivity of 85.1% and a specificity of 55.7%. In 92 women who completed transvaginal US, hysterosonography, and hysteroscopy, hysterosonography was more specific (79.2%; P = .008) but not significantly more sensitive (89.7%; P = .508) than transvaginal US. When women withabnormal transvaginal US findings were further examined with hysterosonography, the sequential combination of transvaginal US and hysterosonography was more specific (77.1%) than transvaginal US alone (P < .001), without a significant decrease in sensitivity (78.7%; P = .25).
CONCLUSION: In asymptomatic postmenopausal women receiving tamoxifen, 6 mm is the optimal endometrial thickness cutoff fordiagnosing endometrial abnormalities with transvaginal US. Further examination with hysterosonography can improve specificity by reducing the high false-positive rate of transvaginal US.
Tamoxifen is widely used in the treatment of breast cancer (1). Although it acts as an antiestrogen in breast tissue, it has estrogenic effects on the endometrium. Long-term tamoxifen therapy is reported to be...